TrialBMC cancer2016

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.

Victor H F Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.